{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T23:16:42Z","timestamp":1788304602411,"version":"build-2803163510"},"reference-count":33,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,8,4]],"date-time":"2026-08-04T00:00:00Z","timestamp":1785801600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,9,2]],"date-time":"2026-09-02T00:00:00Z","timestamp":1788307200000},"content-version":"vor","delay-in-days":29,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/100004319","name":"Pfizer","doi-asserted-by":"publisher","award":["N\/A"],"award-info":[{"award-number":["N\/A"]}],"id":[{"id":"10.13039\/100004319","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Commun"],"DOI":"10.1038\/s41467-026-75871-3","type":"journal-article","created":{"date-parts":[[2026,8,4]],"date-time":"2026-08-04T14:46:32Z","timestamp":1785854792000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["A second yearly booster dose of the VLA15 Lyme borreliosis vaccine candidate in healthy individuals"],"prefix":"10.1038","volume":"17","author":[{"given":"Laura","family":"Wagner","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vera","family":"Kadlecek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jana","family":"Skaroupkova","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicole","family":"Scharnagl","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Romana","family":"Hochreiter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5365-5882","authenticated-orcid":false,"given":"Marc","family":"Messier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juan Carlos","family":"Jaramillo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julian","family":"Larcher-Steiner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lisa","family":"Hegele","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erik","family":"Lamberth","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Timothy","family":"Murphy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jason D.","family":"Maguire","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cheryl","family":"Clarkin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ulla","family":"Derhaschnig","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6059-7094","authenticated-orcid":false,"given":"Susanne","family":"Eder-Lingelbach","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,8,4]]},"reference":[{"key":"75871_CR1","first-page":"333","volume":"42","author":"JD Radolf","year":"2021","unstructured":"Radolf, J. D., Strle, K., Lemieux, J. E. & Strle, F. Lyme disease in humans. Curr. Issues Mol. Biol. 42, 333\u2013384 (2021).","journal-title":"Curr. Issues Mol. Biol."},{"key":"75871_CR2","doi-asserted-by":"publisher","first-page":"461","DOI":"10.1016\/S0140-6736(11)60103-7","volume":"379","author":"G Stanek","year":"2012","unstructured":"Stanek, G., Wormser, G. P., Gray, J. & Strle, F. Lyme borreliosis. Lancet 379, 461\u2013473 (2012).","journal-title":"Lancet"},{"key":"75871_CR3","doi-asserted-by":"publisher","first-page":"616","DOI":"10.3201\/eid2702.202731","volume":"27","author":"KJ Kugeler","year":"2021","unstructured":"Kugeler, K. J., Schwartz, A. M., Delorey, M. J., Mead, P. S. & Hinckley, A. F. Estimating the frequency of Lyme disease diagnoses, United States, 2010-2018. Emerg. Infect. Dis. 27, 616\u2013619 (2021).","journal-title":"Emerg. Infect. Dis."},{"key":"75871_CR4","first-page":"74","volume":"39","author":"RA Sykes","year":"2017","unstructured":"Sykes, R. A. & Makiello, P. An estimate of Lyme borreliosis incidence in Western Europe. J. Public Health 39, 74\u201381 (2017).","journal-title":"J. Public Health"},{"key":"75871_CR5","doi-asserted-by":"publisher","first-page":"569","DOI":"10.1177\/15303667251363125","volume":"25","author":"A Davidson","year":"2025","unstructured":"Davidson, A. et al. Lyme borreliosis incidence across Europe, 2015-2023: a surveillance-based review and analysis. Vector Borne Zoonotic Dis. 25, 569\u2013579 (2025).","journal-title":"Vector Borne Zoonotic Dis."},{"key":"75871_CR6","unstructured":"Centers for Disease Control and Prevention. Lyme disease surveillance data. https:\/\/www.cdc.gov\/lyme\/data-research\/facts-stats\/surveillance-data-1.html (2025)."},{"key":"75871_CR7","doi-asserted-by":"publisher","first-page":"156","DOI":"10.1089\/vbz.2022.0071","volume":"23","author":"L Burn","year":"2023","unstructured":"Burn, L. et al. Incidence of Lyme borreliosis in Europe from national surveillance systems (2005-2020). Vector Borne Zoonotic Dis. 23, 156\u2013171 (2023).","journal-title":"Vector Borne Zoonotic Dis."},{"key":"75871_CR8","doi-asserted-by":"publisher","first-page":"19906","DOI":"10.2807\/ese.16.27.19906-en","volume":"16","author":"A Rizzoli","year":"2011","unstructured":"Rizzoli, A. et al. Lyme borreliosis in Europe. Eur. Surveill. 16, 19906 (2011).","journal-title":"Eur. Surveill."},{"key":"75871_CR9","unstructured":"Bobe, J. R. et al. Recent progress in Lyme disease and remaining challenges. Front. Med. 8, 666554 (2021)."},{"key":"75871_CR10","doi-asserted-by":"publisher","first-page":"449","DOI":"10.1038\/s41584-021-00648-5","volume":"17","author":"RB Lochhead","year":"2021","unstructured":"Lochhead, R. B., Strle, K., Arvikar, S. L., Weis, J. J. & Steere, A. C. Lyme arthritis: linking infection, inflammation and autoimmunity. Nat. Rev. Rheumatol. 17, 449\u2013461 (2021).","journal-title":"Nat. Rev. Rheumatol."},{"key":"75871_CR11","doi-asserted-by":"publisher","first-page":"325","DOI":"10.1016\/j.idc.2015.02.006","volume":"29","author":"PM Lantos","year":"2015","unstructured":"Lantos, P. M. Chronic Lyme disease. Infect. Dis. Clin. North Am. 29, 325\u2013340 (2015).","journal-title":"Infect. Dis. Clin. North Am."},{"key":"75871_CR12","doi-asserted-by":"publisher","first-page":"100142","DOI":"10.1016\/j.lanepe.2021.100142","volume":"6","author":"J Ursinus","year":"2021","unstructured":"Ursinus, J. et al. Prevalence of persistent symptoms after treatment for Lyme Borreliosis: a prospective observational cohort study. Lancet Reg. Health Eur. 6, 100142 (2021).","journal-title":"Lancet Reg. Health Eur."},{"key":"75871_CR13","doi-asserted-by":"publisher","DOI":"10.1016\/j.diagmicrobio.2021.115572","volume":"102","author":"GP Wormser","year":"2022","unstructured":"Wormser, G. P. A brief history of OspA vaccines including their impact on diagnostic testing for Lyme disease. Diagn. Microbiol. Infect. Dis. 102, 115572 (2022).","journal-title":"Diagn. Microbiol. Infect. Dis."},{"key":"75871_CR14","doi-asserted-by":"publisher","first-page":"777","DOI":"10.1111\/zph.12984","volume":"69","author":"AM Schwartz","year":"2022","unstructured":"Schwartz, A. M., Mackeprang, J. M., Mead, P. S. & Hinckley, A. F. Effectiveness of personal protection measures against Lyme disease: a review of epidemiologic studies from the United States. Zoonoses Public Health 69, 777\u2013791 (2022).","journal-title":"Zoonoses Public Health"},{"key":"75871_CR15","doi-asserted-by":"publisher","first-page":"216","DOI":"10.1056\/NEJM199807233390402","volume":"339","author":"LH Sigal","year":"1998","unstructured":"Sigal, L. H. et al. A vaccine consisting of recombinant Borrelia burgdorferi outer-surface protein A to prevent Lyme disease. N. Engl. J. Med. 339, 216\u2013222 (1998).","journal-title":"N. Engl. J. Med."},{"key":"75871_CR16","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1056\/NEJM199807233390401","volume":"339","author":"AC Steere","year":"1998","unstructured":"Steere, A. C. et al. Vaccination against Lyme disease with recombinant Borrelia burgdorferi outer-surface lipoprotein A with adjuvant. N. Engl. J. Med. 339, 209\u2013215 (1998).","journal-title":"N. Engl. J. Med."},{"key":"75871_CR17","doi-asserted-by":"publisher","first-page":"680","DOI":"10.1016\/S1473-3099(13)70110-5","volume":"13","author":"N Wressnigg","year":"2013","unstructured":"Wressnigg, N. et al. Safety and immunogenicity of a novel multivalent OspA vaccine against Lyme borreliosis in healthy adults: a double-blind, randomised, dose-escalation phase 1\/2 trial. Lancet Infect. Dis. 13, 680\u2013689 (2013).","journal-title":"Lancet Infect. Dis."},{"key":"75871_CR18","doi-asserted-by":"publisher","DOI":"10.1038\/s41541-022-00429-5","volume":"7","author":"RJ Dattwyler","year":"2022","unstructured":"Dattwyler, R. J. & Gomes-Solecki, M. The year that shaped the outcome of the OspA vaccine for human Lyme disease. NPJ Vaccines 7, 10 (2022).","journal-title":"NPJ Vaccines"},{"key":"75871_CR19","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1084\/jem.183.1.271","volume":"183","author":"AM de Silva","year":"1996","unstructured":"de Silva, A. M., Telford, S. R. I., Brunet, L. R., Barthold, S. W. & Fikrig, E. Borrelia burgdorferi OspA is an arthropod-specific transmission-blocking Lyme disease vaccine.  J. Exp. Med. 183, 271\u2013275 (1996).","journal-title":"J. Exp. Med."},{"key":"75871_CR20","doi-asserted-by":"publisher","first-page":"1551","DOI":"10.1016\/S0264-410X(97)00066-2","volume":"15","author":"L Gern","year":"1997","unstructured":"Gern, L., Hu, C. M., Voet, P., Hauser, P. & Lobet, Y. Immunization with a polyvalent OspA vaccine protects mice against Ixodes ricinus tick bites infected by Borrelia burgdorferi ss, Borrelia garinii and Borrelia afzelii. Vaccine 15, 1551\u20131557 (1997).","journal-title":"Vaccine"},{"key":"75871_CR21","doi-asserted-by":"publisher","first-page":"210","DOI":"10.1016\/S0149-2918(03)90027-0","volume":"25","author":"RT Schoen","year":"2003","unstructured":"Schoen, R. T., Deshefy-Longhi, T., Van-Hoecke, C., Buscarino, C. & Fikrig, E. An open-label, nonrandomized, single-center, prospective extension, clinical trial of booster dose schedules to assess the safety profile and immunogenicity of recombinant outer-surface protein A (OspA) Lyme disease vaccine. Clin. Ther. 25, 210\u2013224 (2003).","journal-title":"Clin. Ther."},{"key":"75871_CR22","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1542\/peds.108.1.123","volume":"108","author":"VK Sikand","year":"2001","unstructured":"Sikand, V. K. et al. Safety and immunogenicity of a recombinant Borrelia burgdorferi outer surface protein A vaccine against Lyme disease in healthy children and adolescents: a randomized controlled trial. Pediatrics 108, 123\u2013128 (2001).","journal-title":"Pediatrics"},{"key":"75871_CR23","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1016\/S0149-2918(00)80035-1","volume":"22","author":"RT Schoen","year":"2000","unstructured":"Schoen, R. T. et al. Safety and immunogenicity profile of a recombinant outer-surface protein A Lyme disease vaccine: clinical trial of a 3-dose schedule at 0, 1, and 2 months. Clin. Ther. 22, 315\u2013325 (2000).","journal-title":"Clin. Ther."},{"key":"75871_CR24","doi-asserted-by":"publisher","first-page":"1764","DOI":"10.1001\/jama.1994.03510460056033","volume":"271","author":"D Keller","year":"1994","unstructured":"Keller, D. et al. Safety and immunogenicity of a recombinant outer surface protein A Lyme vaccine. J. Am. Med. Assoc. 271, 1764\u20131768 (1994).","journal-title":"J. Am. Med. Assoc."},{"key":"75871_CR25","doi-asserted-by":"publisher","first-page":"1260","DOI":"10.1086\/514779","volume":"28","author":"C Van Hoecke","year":"1999","unstructured":"Van Hoecke, C., Lebacq, E., Beran, J. & Parenti, D. Alternative vaccination schedules (0, 1, and 6 months versus 0, 1, and 12 months) for a recombinant OspA Lyme disease vaccine. Clin. Infect. Dis. 28, 1260\u20131264 (1999).","journal-title":"Clin. Infect. Dis."},{"key":"75871_CR26","doi-asserted-by":"publisher","first-page":"e113294","DOI":"10.1371\/journal.pone.0113294","volume":"9","author":"P Comstedt","year":"2014","unstructured":"Comstedt, P., Hanner, M., Schuler, W., Meinke, A. & Lundberg, U. Design and development of a novel vaccine for protection against Lyme borreliosis. PloS ONE 9, e113294 (2014).","journal-title":"PloS ONE"},{"key":"75871_CR27","doi-asserted-by":"publisher","first-page":"5982","DOI":"10.1016\/j.vaccine.2015.07.095","volume":"33","author":"P Comstedt","year":"2015","unstructured":"Comstedt, P. et al. Characterization and optimization of a novel vaccine for protection against Lyme borreliosis. Vaccine 33, 5982\u20135988 (2015).","journal-title":"Vaccine"},{"key":"75871_CR28","doi-asserted-by":"publisher","first-page":"1186","DOI":"10.1016\/S1473-3099(23)00210-4","volume":"23","author":"N B\u00e9zay","year":"2023","unstructured":"B\u00e9zay, N. et al. Safety and immunogenicity of a novel multivalent OspA-based vaccine candidate against Lyme borreliosis: a randomised, phase 1 study in healthy adults. Lancet Infect. Dis. 23, 1186\u20131196 (2023).","journal-title":"Lancet Infect. Dis."},{"key":"75871_CR29","doi-asserted-by":"publisher","first-page":"1045","DOI":"10.1016\/S1473-3099(24)00175-0","volume":"24","author":"N B\u00e9zay","year":"2024","unstructured":"B\u00e9zay, N. et al. Optimisation of dose level and vaccination schedule for the VLA15 Lyme borreliosis vaccine candidate among healthy adults: two randomised, observer-blind, placebo-controlled, multicentre phase 2 studies. Lancet Infect. Dis. 24, 1045\u20131058 (2024).","journal-title":"Lancet Infect. Dis."},{"key":"75871_CR30","doi-asserted-by":"publisher","first-page":"986","DOI":"10.1016\/S1473-3099(25)00092-1","volume":"25","author":"L Wagner","year":"2025","unstructured":"Wagner, L. et al. Immunogenicity and safety of different immunisation schedules of the VLA15 Lyme borreliosis vaccine candidate in adults, adolescents, and children: a randomised, observer-blind, placebo-controlled, phase 2 trial. Lancet Infect. Dis. 25, 986\u2013999 (2025).","journal-title":"Lancet Infect. Dis."},{"key":"75871_CR31","doi-asserted-by":"publisher","first-page":"1275","DOI":"10.1016\/S1473-3099(24)00372-4","volume":"24","author":"SK Ghadge","year":"2024","unstructured":"Ghadge, S. K. et al. Immunogenicity and safety of an 18-month booster dose of the VLA15 Lyme borreliosis vaccine candidate after primary immunisation in healthy adults in the USA: results of the booster phase of a randomised, controlled, phase 2 trial. Lancet Infect. Dis. 24, 1275\u20131286 (2024).","journal-title":"Lancet Infect. Dis."},{"key":"75871_CR32","doi-asserted-by":"publisher","first-page":"314","DOI":"10.1016\/S1473-3099(25)00541-9","volume":"26","author":"L Wagner","year":"2026","unstructured":"Wagner, L. et al. Immunogenicity and safety of an 18-month booster dose of the VLA15 Lyme borreliosis vaccine candidate after primary immunisation in children, adolescents, and adults in the USA: a randomised, observer-blind, placebo-controlled, phase 2 trial. Lancet Infect. Dis. 26, 314\u2013328 (2026).","journal-title":"Lancet Infect. Dis."},{"key":"75871_CR33","doi-asserted-by":"publisher","first-page":"601","DOI":"10.1007\/s00431-012-1924-0","volume":"172","author":"M Knuf","year":"2013","unstructured":"Knuf, M. et al. Immunogenicity and safety of the quadrivalent meningococcal serogroups A, C, W-135 and Y tetanus toxoid conjugate vaccine (MenACWY-TT) in 2-10-year-old children: results of an open, randomised, controlled study. Eur. J. Pediatr. 172, 601\u2013612 (2013).","journal-title":"Eur. J. Pediatr."}],"container-title":["Nature Communications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41467-026-75871-3","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-026-75871-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-026-75871-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T22:49:17Z","timestamp":1788302957000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41467-026-75871-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,4]]},"references-count":33,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["75871"],"URL":"https:\/\/doi.org\/10.1038\/s41467-026-75871-3","relation":{},"ISSN":["2041-1723"],"issn-type":[{"value":"2041-1723","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,4]]},"assertion":[{"value":"14 April 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 July 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 August 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"L.W., V.K., J.S., N.S., R.H., M.M., J.C.J., and S.E.-L. are current or former employees of Valneva and may hold stock or stock options. J.L.-S., L.H., and U.D. are paid consultants for Valneva. E.L., T.M., J.D.M., and C.C. are current or former employees of Pfizer Inc and may hold stock or stock options.","order":1,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Ethics"}}],"article-number":"9386"}}